Trillium Therapeutics Inc (TRIL)

[NY1972]

Assessment of Minimal Residual Disease in Standard-Risk AML

The analyses confirmed that the presence of minimal residual disease in peripheral blood on RT-qPCR assay after the second chemotherapy cycle predicted a worse outcome at 2 years than did the absence of minimal residual disease, with an increased cumulative incidence of relapse (70% vs. 31%, P=0.001) and a lower rate of overall survival (40% vs. 87%, P=0.001)

http://www.nejm.org/doi/full/10.1056/NEJMoa1507471#t=article